{"id":"W2418506270","doi":"10.1056/nejmoa1512711","title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":838,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Etanercept; Placebo; Plaque psoriasis; Clinical trial; Interleukin 17; Dermatology; Internal medicine; Tumor necrosis factor alpha; Alternative medicine; Secukinumab; Inflammation; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004583307,0.0008577029,0.001723042,0.0003028556,0.0005627394,0.0007981441,0.0007986637,0.001099682,0.004923496],"category_scores_gemma":[0.002510791,0.0003896945,0.001623965,0.0003781976,0.0007136192,0.0005147167,0.00049335,0.003387888,0.0005940376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000593358,"about_ca_system_score_gemma":0.001465435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004468698,"about_ca_topic_score_gemma":0.001308327,"domain_scores_codex":[0.9986065,0.0009263102,0.0000818373,0.0001059075,0.0001455962,0.0001339616],"domain_scores_gemma":[0.9981193,0.0005176724,0.0004410532,0.0001645768,0.0001488728,0.0006085031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8785774,0.02019189,0.004906696,0.001767958,0.001905875,0.0001486208,0.0001388554,0.0009187459,0.01187427,0.000499393,0.00830093,0.0707694],"study_design_scores_gemma":[0.8949127,0.09290014,0.005737209,0.00009451998,0.0005170724,0.0001939409,0.00002495818,0.0002974982,0.001013927,0.0005043294,0.003787918,0.00001581176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9597977,0.01789124,0.001808035,0.002518733,0.0007508641,0.009077652,0.002396259,0.000174192,0.005585243],"genre_scores_gemma":[0.9761228,0.005573062,0.003061332,0.002588648,0.0006490978,0.007799034,0.001852174,0.00003244166,0.002321483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004923496,"threshold_uncertainty_score":0.02423918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04471593433998027,"score_gpt":0.3116114006828535,"score_spread":0.2668954663428732,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}